AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04051957
Drug: Isosorbide Mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
Trial: NCT03423979
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
Trial: NCT02760342
Drug: peficitinib
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT02760342
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT01175746
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04003402
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01400412
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
Trial: NCT01400412
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
Trial: NCT01400412
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
Trial: NCT01400412
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine was administered orally once a day as one 200 mg capsule.
Trial: NCT01400412
Drug: Placebo for Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
Trial: NCT01400412
Drug: Placebo for Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for maraviroc was administered orally once a day as one tablet.
Trial: NCT01400412
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc was administered orally once a day as one 150 mg tablet.
Trial: NCT03599713
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
Trial: NCT01649869
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
Trial: NCT03934294
Drug: Metoclopramide 10mg
RxNorm normalized name: METOCLOPRAMIDE 10MG ORAL DISINTEGRAT TAB
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
Trial: NCT01108874
Drug: Metaraminol
RxNorm normalized name: Metaraminol
DrugBank: Metaraminol (DB00610)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given metaraminol every time SBP falls below baseline value.
Trial: NCT02051946
Drug: ethacrynic acid injection
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02051946
Drug: balanced salt solution
RxNorm normalized name: Balanced Salt Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01817400
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01817400
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
Trial: NCT03148002
Drug: Current Bowel Protocol (senna/lactulose)
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stimulant and Osmotic Laxatives.
Trial: NCT03168308
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex 2 mg/kg
Trial: NCT03168308
Drug: Neostigmine w/ Glycopyrrolate
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
Trial: NCT03906045
Drug: BGF-MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, Glycopyrronium and Formoterol Fumarate.
Trial: NCT00999557
Drug: bimatoprost ophthalmic solution
RxNorm normalized name: Bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied topically
Trial: NCT03204305
Drug: 11C-OMAR
RxNorm normalized name: 11C-OMAR
DrugBank: JHU-75528 C-11 (DB14902)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
Trial: NCT00867334
Drug: Imatinib mesylate and panitumumab
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
Trial: NCT00867334
Drug: Standard-of-care treatment with panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
Trial: NCT03921567
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
Trial: NCT03921567
Drug: Lidocaine Hydrochloride and Ketamine
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
Trial: NCT04687930
Drug: genicular nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
Trial: NCT03204305
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
Trial: NCT00952692
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
Trial: NCT02474173
Drug: Onalespib
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02474173
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00270556
Drug: tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00270556
Drug: Abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04189614
Drug: Cofetuzumab Pelidotin
RxNorm normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT02697448
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant receives propofol as anesthetic for cardiac ablation.
Trial: NCT02697448
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant receives sevoflurane as anesthetic for cardiac ablations.
Trial: NCT04258631
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT04258631
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT04833738
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04833738
Drug: Corticosteroids Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamcinolone acetonide, 40 mg/ml, single dose
Trial: NCT03685149
Drug: Flecainide Pill
RxNorm normalized name: flecainide Pill
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Trial: NCT01370044
Drug: Carbogen
RxNorm normalized name: carbogen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 minutes administration of carbogen
Trial: NCT03864328
Drug: RVT-1601
RxNorm normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled RVT-1601 administered TID via eFlow nebulizer
Trial: NCT02096354
Drug: RRx-001
RxNorm normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02096354
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02096354
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To be dosed after RRx-001 or regorafenib
Trial: NCT00167245
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/day for 13 weeks
Trial: NCT00347971
Drug: recombinant human interleukin 21 and rituximab
RxNorm normalized name: Recombinant Human Interleukin-12
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
Trial: NCT04240509
Drug: Emtricitabine / Tenofovir
RxNorm normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
Trial: NCT03162627
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Trial: NCT03162627
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase.
Trial: NCT02172157
Drug: BI 1744 CL oral
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00374179
Drug: CT-322
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV solution, weekly or bi-weekly
Trial: NCT01767987
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
Trial: NCT02835105
Drug: Surotomycin
RxNorm normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
Trial: NCT00113373
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT04148209
Drug: PF-07081532
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single ascending doses PF-07081532
Trial: NCT02014376
Drug: Vehicle (SD-101 0%)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
Trial: NCT01202162
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administratino of Desflurane
Trial: NCT01202162
Drug: Administration of Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Sevoflurane
Trial: NCT00219726
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01172392
Drug: Pegylated interferon-alpha-2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mcg / wk / SC from D0 to W48
Trial: NCT03469895
Drug: ibrutinib ou idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: treatment by ibrutinib or idelalisib for autoimmune cytopenia
Trial: NCT00086515
Drug: Sitagliptin (MK0431)
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
Trial: NCT00086515
Drug: Placebo/Glipizide 5 mg
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
Trial: NCT00086515
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
Trial: NCT00086515
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
Trial: NCT02495883
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta blocker
Trial: NCT00105066
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850mg tablet once a day for one month, then twice a day for 3 months
Trial: NCT00209131
Drug: Flomax
RxNorm normalized name: Flomax
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
Trial: NCT00209131
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
Trial: NCT02796651
Drug: Formoterol fumarate (6 μg)
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Trial: NCT02796651
Drug: Formoterol furmarate (20 μg)
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Trial: NCT02796651
Drug: Placebo for formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Trial: NCT02796651
Drug: Formoterol fumarate (12 μg)
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Trial: NCT02796651
Drug: Formoterol fumarate (40 μg)
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Trial: NCT00619866
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix tablets administered orally
Trial: NCT02268656
Drug: propofol concentration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
Trial: NCT01380080
Drug: Atripla (r)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
Trial: NCT01380080
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take one 600 mg tablet administered orally once daily without food.
Trial: NCT01380080
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
Trial: NCT01380080
Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
Trial: NCT01380080
Drug: Rifampin/isoniazid FDC
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
Trial: NCT01380080
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INH 300 mg orally once daily